$47.89
arrow_drop_up1.56%Key Stats | |
---|---|
Open | $47.69 |
Prev. Close | $47.36 |
EPS | -6.45 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 46.91 | 50.76 |
52 Week Range | 31.52 | 60.37 |
Ratios | |
---|---|
EPS | -6.45 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Leerink Partners upgrades Ionis stock on key asset commercialization - Investing.com